Micro Digital Co., Ltd.

Micro Digital Co., Ltd.

KKRX:305090
538.00
KRW
-230.00
(-29.95%)
-1,124.65EPS
40.82BMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
301.06
573.54
491.87
147.76
157.73
292.3
567.14
697.99
718.34
720.03
555.73
Basic EPS, GAAP
-226.19
-3.75
-172.5
-237
-721
-518
-596
38
28
-737
-1,124.65
Free Cash Flow per Basic Share
10.84
-1.97
-230.17
-315.13
-687.92
-625.46
-527.96
-361.82
-549.71
-756.75
-730.63
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
34.47
29.44
614.64
1,226.27
525.94
843.6
345.23
555.22
1,737.08
1,551.23
810.64
Tangible Book Value per Share
20.02
18.78
613.56
1,185.16
482.44
802.67
294.79
519.77
1,708.22
1,478.86
741.72
Basic Weighted Avg Shares
15
8
10
27
15
15
16
16
16
18
18
Sales/Revenue/Turnover
4,372
4,554
4,723
3,926
2,290
4,305
8,884
10,840
11,533
12,843
10,108
Operating Margin (%)
0.74
10.82
-25.98
-162.28
-458.95
-149.25
-89.52
8.12
2.43
-71.41
-157.42
Depreciation Expense
66
92
224
900
1,478
1,492
1,774
1,904
1,952
2,345
2,054
Net Income, GAAP
-3,285
-30
-1,657
-6,297
-10,469
-7,628
-9,336
590
450
-13,146
-20,456
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
0.09
- -
- -
- -
Profit Margin (%)
-75.13
-0.65
-35.07
-160.39
-457.11
-177.21
-105.09
5.44
3.9
-102.36
-202.37
Working Capital
1,335
444
7,811
14,446
2,217
13,485
326
393
32,056
24,993
9,451
LT Debt
1,767
347
217
1,036
3,389
10,471
4,047
3,397
10,630
9,418
9,966
Total Equity
498
425
8,875
17,809
7,638
12,425
5,437
8,717
29,136
28,953
15,173
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
4.33
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
9.59
- -
- -
- -
Return on Common Equity (%)
- -
-6.45
-35.62
-47.2
-82.28
-76.7
-107.4
8.54
2.39
-45.53
-90.04

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
13,862
13,986
14,146
LT Borrowings
9,262
9,565
9,898
LT Finance Leases
156
109
68
Preferred Equity and Hybrid Capital
108
108
99
Shares Outstanding
19
19
19
Market Capitalization
201,198
105,248
40,816

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
43,412
36,062
27,723
Cash, Cash Equivalents & STI
17,763
13,356
8,338
Accounts Receivable, Net
7,970
7,707
6,920
Inventories
7,855
8,774
7,808
Total Current Liabilities
18,419
18,827
18,272
Payables & Accruals
- -
- -
- -
ST Debt
13,862
13,986
14,146
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
60.08%
-0.63%
Free Cash Flow
- -
11.99%
52.93%
Net Income, GAAP
- -
-631.81%
-3,024.14%
Sales/Revenue/Turnover
- -
46.82%
11.35%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,685
2,425
2,293
4,130
11,533
2025
3,156
3,240
3,978
2,469
12,843
2026
2,525
1,136
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
42
-30
19.01
28
2025
-70
-199
-12.94
-430.19
-737
2026
-229.34
-434
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Kyung-Nam Kim
Full Time Employees
86
Sector
Health technology
Industry
Medical specialties
Address
Seongnam-si South Korea
IPO Date
Jun 5, 2019
Business
Micro Digital Co., Ltd. is a South Korea-based biomedical engineering and life sciences equipment company specializing in the development, manufacture, and distribution of bioprocess systems, automated diagnostic platforms, and precision analytical laboratory instrumentation. Founded in 2002 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, the company serves biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), academic and clinical research institutes, and cellular agriculture enterprises across the Asia-Pacific, North American, and European markets. Micro Digital Co., Ltd. organizes its commercial operations into three primary business divisions: Bioprocess Systems, Biomedical Laboratory Instruments, and In Vitro Diagnostic Solutions. The Bioprocess Systems segment manufactures the proprietary CELBIC series of single-use bioreactors featuring orbital rocking mixing mechanisms for low-shear, high-density cell culture across scalable volumes ranging from 5 liters to 1,000 liters (including the CELBIC 5, CELBIC 100, CELBIC 200, CELBIC 500, and CELBIC 1000 models); single-use bioprocessing consumables, encompassing three-dimensional disposable culture bags, two-dimensional liquid storage and transfer bags, tube manifolds, and aseptic sampling systems; and bioprocess engineering consulting services. The Biomedical Laboratory Instruments segment develops optical analytical devices, comprising the Nabi micro-volume ultraviolet-visible (UV/Vis) nano spectrophotometer; the Mobi microplate spectrophotometer; the Ubi series spectrophotometric instruments (Ubi-490, Ubi-600, and Ubi-800); the Lumi single-tube and Lubi Plus microplate luminescence readers; and the iSBS automated sample banking and liquid handling system. The In Vitro Diagnostic Solutions segment supplies the DxBIC automated immunoassay system for high-throughput clinical sample processing; diagnostic cartridge consumables; and integrated laboratory automation robotics. In recent strategic developments, Micro Digital Co., Ltd. expanded its global commercialization reach by entering into a supply and distribution partnership with U.S.-based motion and control leader Parker Hannifin, introducing its single-use bioreactor technology into the North American biomanufacturing market under Parker Hannifin's OrbTec brand. The company has also broadened its industrial application scope through bioprocess development agreements with cultivated meat technology developers, including SeaWith, to optimize large-scale cell biomass production using CELBIC systems. Furthermore, Micro Digital Co., Ltd. has initiated strategic research and development initiatives focused on artificial intelligence-enabled bioprocessing platforms and cloud-connected automation, while managing corporate governance adjustments and listing compliance procedures on the KOSDAQ market.